GLP-1 receptor agonists activate one pathway.
A GLP-1 receptor agonist is a medicine that turns on the glucagon-like peptide-1 receptor, also called the GLP-1 receptor. These medicines help the body release insulin when glucose is high, reduce glucagon, slow stomach emptying, and send stronger fullness signals to the brain.
🔑 Key Takeaways
- GLP-1 receptor agonists are prescription medicines that mimic the incretin hormone GLP-1 at the GLP-1 receptor.
- The main GLP-1 agonist drug list includes exenatide, liraglutide, lixisenatide, dulaglutide, semaglutide, and newer oral or dual-agonist medicines that activate the GLP-1 receptor.
- GLP-1 receptor agonists for type 2 diabetes help lower A1C with a low standalone risk of hypoglycemia because insulin release is glucose-dependent.
- GLP-1 receptor agonists for weight loss work mostly through appetite, satiety, food noise, and delayed gastric emptying.
- Tirzepatide is often included in GLP-1 agonist lists, but it is more precise to call it a dual GIP and GLP-1 receptor agonist.
This page is the plain-English GLP-1 agonist drug list: what the receptor does, which medicines are in the class, how they differ, and why the same drug names keep showing up in both type 2 diabetes and weight-loss conversations.
GLP-1 Receptor Agonist List
Start with the names.
The table below keeps the class organized by active ingredient first, then brand name. That matters because Ozempic, Wegovy, and Rybelsus are all semaglutide, while Mounjaro and Zepbound are both tirzepatide.
| Active Ingredient | Common Brand Names | Route / Frequency | Main Use | What To Know |
|---|---|---|---|---|
| Exenatide | Byetta, Bydureon BCise | Twice daily or weekly injection, depending on product | Type 2 diabetes | Older GLP-1 agonist; first in class |
| Liraglutide | Victoza, Saxenda | Daily injection | Type 2 diabetes or weight management, depending on brand | Strong history, but daily dosing is less convenient |
| Lixisenatide | Adlyxin | Daily injection | Type 2 diabetes | Shorter-acting option, often discussed less than newer weekly drugs |
| Dulaglutide | Trulicity | Weekly injection | Type 2 diabetes | Common diabetes-focused weekly GLP-1 receptor agonist medicine |
| Semaglutide | Ozempic, Wegovy, Rybelsus, Wegovy pill | Weekly injection or daily oral tablet | Type 2 diabetes, weight management, cardiovascular risk reduction in specific groups | Most searched true GLP-1 receptor agonist |
| Tirzepatide | Mounjaro, Zepbound | Weekly injection | Type 2 diabetes or weight management, depending on brand | Dual GIP and GLP-1 receptor agonist; included because it activates GLP-1 receptor signaling |
| Orforglipron | Foundayo | Daily oral tablet | Weight management | Small-molecule oral GLP-1 receptor agonist; simpler routine than oral semaglutide |
This is the practical GLP-1 agonist list most readers need. Some older or non-U.S. agents also appear in medical literature, including albiglutide and peg-loxenatide, but they are not the names most U.S. readers are deciding between today.
What Is a GLP-1 Receptor Agonist?
It is a receptor activator.
GLP-1 stands for glucagon-like peptide-1. Natural GLP-1 is an incretin hormone released after eating. A glucagon-like peptide-1 (GLP-1) agonist is built to mimic enough of that hormone’s signal to activate the GLP-1 receptor.
An agonist is not just something that “binds.” It binds and turns the receptor on. That is why the phrase GLP-1 receptor agonist is more exact than “GLP-1 drug.” These medicines are trying to make the receptor behave as if the body’s own GLP-1 signal is stronger or longer-lasting.
Simple version
A GLP-1 agonist is a medicine that presses the GLP-1 receptor button. That button helps regulate blood sugar, appetite, fullness, and gastric emptying.
What the GLP-1 Receptor Does
The receptor connects several systems.
The GLP-1 receptor is found in places that matter for metabolism: the pancreas, gut, brain, heart, kidney, and nervous-system signaling pathways. That is why one class of medicines can affect glucose, appetite, weight, and cardiometabolic risk at the same time.
| Location / System | GLP-1 Receptor Effect | What Users Notice |
|---|---|---|
| Pancreas | Increases insulin release when glucose is elevated | Lower post-meal glucose and A1C |
| Alpha cells | Reduces glucagon when it is too high | Less liver glucose output after meals |
| Stomach | Slows gastric emptying | Fullness lasts longer, large meals feel harder |
| Brain appetite circuits | Increases satiety and reduces food reward for many people | Less hunger and less food noise |
| Heart and blood vessels | May improve cardiovascular outcomes in selected patients and drugs | Risk reduction becomes part of drug selection |
| Kidney-metabolic pathways | May support kidney outcomes in selected populations | Important for people with diabetes and kidney risk |
This is why GLP-1 receptor agonist medicines are no longer only “diabetes shots.” The same receptor biology now shows up in obesity, cardiovascular-risk, kidney-risk, sleep apnea, and liver-health discussions.
GLP-1 Agonists for Type 2 Diabetes
Diabetes came first.
GLP-1 receptor agonists for type 2 diabetes were developed to improve glucose control without forcing insulin release when glucose is already low. That glucose-dependent insulin effect is one reason the class is useful: by itself, a GLP-1 receptor agonist has a low risk of causing hypoglycemia compared with insulin or sulfonylureas.
The main goals in type 2 diabetes are usually A1C reduction, post-meal glucose control, weight support, and lower cardiometabolic risk in patients who have heart, kidney, or obesity-related complications.
| Diabetes-Focused Medicine | Active Ingredient | Typical Role | Why It Gets Picked |
|---|---|---|---|
| Ozempic | Semaglutide | Weekly glucose control with weight-loss effect | Strong A1C and weight profile |
| Rybelsus | Oral semaglutide | Needle-free diabetes GLP-1 option | Oral route, but strict administration routine |
| Trulicity | Dulaglutide | Weekly type 2 diabetes treatment | Familiar diabetes option with cardiovascular-outcome data |
| Victoza | Liraglutide | Daily GLP-1 treatment | Older option with long clinical history |
| Byetta / Bydureon | Exenatide | Older GLP-1 agonist options | First-generation class history |
| Mounjaro | Tirzepatide | Diabetes treatment with strong weight loss | Dual GIP and GLP-1 activity |
For broader diabetes and weight-loss positioning, see our what is GLP-1 explainer and how GLP-1 works.
GLP-1 Receptor Agonists for Weight Loss
Weight loss changed the category.
GLP-1 receptor agonists for weight loss are prescribed at obesity-focused doses and labels, not just diabetes doses. The best-known examples are Wegovy, Saxenda, Zepbound, and newer oral weight-management options.
| Weight-Loss Brand | Active Ingredient | Class Precision | Main Advantage | Main Limitation |
|---|---|---|---|---|
| Wegovy | Semaglutide | True GLP-1 receptor agonist | Established weekly obesity treatment | Less average weight loss than tirzepatide in direct comparison |
| Wegovy HD | Semaglutide 7.2 mg | Higher-dose true GLP-1 receptor agonist | Stronger semaglutide weight-loss option | Newer dose, higher tolerability demands |
| Wegovy pill | Oral semaglutide | Oral GLP-1 receptor agonist | Needle-free semaglutide | Daily dosing and food/water timing rules |
| Saxenda | Liraglutide | True GLP-1 receptor agonist | Older daily obesity option | Daily injections and lower average loss |
| Zepbound | Tirzepatide | Dual GIP and GLP-1 receptor agonist | Highest practical weight-loss ranking among available options | Injection, GI effects, cost, and supply friction |
| Foundayo | Orforglipron | Oral GLP-1 receptor agonist | No food or water timing restrictions | Lower average loss than top injections |
If your main question is which option performs best for body weight, read best GLP-1 for weight loss. If the main issue is cost, use the GLP-1 without insurance guide.
GLP-1 Medicines by Route
Route changes adherence.
Most early GLP-1 agonist drugs were injections. Newer oral options matter because some people simply will not start a weekly shot, even when the data are strong.
| Route | Examples | Best Fit | Tradeoff |
|---|---|---|---|
| Weekly injection | Ozempic, Wegovy, Trulicity, Mounjaro, Zepbound | People who want simple weekly dosing | Injection comfort, shortages, and dose escalation |
| Daily injection | Victoza, Saxenda, Byetta, Adlyxin | People who fit older products or specific coverage rules | More frequent dosing |
| Oral tablet | Rybelsus, Wegovy pill, Foundayo | People who want needle-free treatment | Daily adherence; oral semaglutide has strict administration rules |
| Future / pipeline | Retatrutide and other multi-agonists | Not routine first-line choices today | Availability and long-term safety data determine future use |
True GLP-1 Agonists vs Dual Agonists
The wording matters.
Semaglutide, liraglutide, dulaglutide, exenatide, and lixisenatide are classic GLP-1 receptor agonists. Tirzepatide activates the GLP-1 receptor too, but it also activates the GIP receptor. That makes it a dual agonist, not a pure GLP-1-only drug.
In everyday search language, people still call tirzepatide a GLP-1. That is understandable because the GLP-1 receptor is part of its effect. But if you are comparing mechanisms, it is more accurate to separate:
- Single GLP-1 receptor agonists: semaglutide, liraglutide, dulaglutide, exenatide, lixisenatide.
- Dual GIP and GLP-1 receptor agonists: tirzepatide.
- Triple agonists: retatrutide, which targets GIP, GLP-1, and glucagon receptors and remains a next-generation comparison topic.
- Amylin plus GLP-1 combinations: CagriSema-style approaches, where a different satiety pathway is added to semaglutide.
For next-generation comparisons, see retatrutide vs tirzepatide and Foundayo orforglipron.
Benefits Beyond A1C and Weight
The class keeps expanding.
The strongest original use was type 2 diabetes. Then obesity became the public story. Now the class is also being evaluated and used around cardiovascular risk, kidney outcomes, sleep apnea, liver disease, and broader metabolic health.
| Potential Benefit Area | Why GLP-1 Receptor Agonists Matter | Important Caveat |
|---|---|---|
| Blood glucose | Increase glucose-dependent insulin and lower glucagon | Still part of a full diabetes plan, not a substitute for monitoring |
| Weight management | Reduce appetite, food noise, and meal size | Lean-mass protection requires protein and resistance training |
| Cardiovascular risk | Some GLP-1 medicines have outcome data in selected high-risk groups | Benefit depends on drug, population, and indication |
| Kidney outcomes | Semaglutide and other incretin therapies are increasingly discussed in kidney-risk care | Kidney disease needs individualized supervision |
| Sleep apnea and liver health | Weight loss and direct metabolic effects may improve related conditions | Still depends on diagnosis and medical follow-up |
Side Effects and Risks
Most problems start in digestion.
The most common side effects are nausea, constipation, diarrhea, vomiting, reflux, burping, appetite dropping too far, and injection-site reactions. These usually appear during dose escalation or after a dose increase.
More serious concerns are less common but important: pancreatitis symptoms, gallbladder disease, dehydration-related kidney problems, severe allergic reactions, worsening retinopathy in some diabetes contexts, and severe stomach-emptying problems. Many GLP-1 labels also carry warnings around medullary thyroid carcinoma risk and multiple endocrine neoplasia type 2.
When to slow down
If nausea, vomiting, constipation, reflux, or low food intake becomes the main story, chasing the next dose is usually the wrong move. Tolerability is what keeps people on treatment long enough to benefit.
Who Should Avoid or Use Caution?
Some histories change the risk.
GLP-1 receptor agonist medicines require clinician review, especially if you have a history of pancreatitis, gallbladder disease, gastroparesis, severe reflux, kidney disease, diabetic retinopathy, pregnancy plans, breastfeeding, eating-disorder history, or use insulin or sulfonylureas.
They also should not be layered casually. Combining a GLP-1 agonist with another GLP-1 agonist or a DPP-4 inhibitor is usually not the intended treatment strategy. The point is to choose a coherent plan, not stack overlapping incretin signals without medical reason.
How to Read a GLP-1 Drug List
Use three filters.
When you see a GLP-1 agonist drug list online, do not compare brand names only. Compare active ingredient, receptor mechanism, and labeled use.
- Active ingredient: semaglutide, tirzepatide, liraglutide, dulaglutide, exenatide, lixisenatide, orforglipron.
- Mechanism: true GLP-1 receptor agonist, dual GIP/GLP-1 agonist, or next-generation multi-agonist.
- Labeled use: type 2 diabetes, chronic weight management, cardiovascular-risk reduction, or another specific indication.
- Route: weekly injection, daily injection, or oral tablet.
- Access: retail pharmacy, direct-pay program, insurance coverage, telehealth, or specialist clinic.
This keeps the list useful instead of just long.
Frequently Asked Questions
Sources
- Cleveland Clinic: GLP-1 agonists, list, mechanism, uses, and side effects
- National Kidney Foundation: GLP-1 receptor agonists and kidney-risk context
- American Diabetes Association: Standards of Care in Diabetes 2026 release
- NCBI Bookshelf / StatPearls: Glucagon-like peptide-1 receptor agonists
- Mayo Clinic: Diabetes drugs and weight loss
- The Lancet: GLP-1 receptor agonists and next-generation incretin medicines
- Nature Communications: Umbrella review of GLP-1 receptor agonist outcomes
- National Academy of Medicine: Understanding GLP-1 drugs, cost, safety, and access